A Study to Assess Hemoglobin Level Depending on the Comorbidity Index in Chronic Kidney Disease (CKD) Participants Not in Dialysis Treated With Methoxy Polyethylene Glycol-Epoetin Beta (COMETE)

Hemoglobin Levels According to Liu Index and Resistance Factors

Time frame: Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9

Average Dose of Mircera in Total Population

Time frame: Baseline up to 9 months

Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) in Total Population

Time frame: Baseline up to 9 months

Average Dose of Mircera in Subgroups as Defined by the Comorbidities List Used for the Charlson Comorbidities Index Calculation

Time frame: Baseline up to 9 months

Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) in in Subgroups as Defined by the Comorbidities List Used for the Charlson Comorbidities Index Calculation

Time frame: Baseline up to 9 months

Duration of Treatment With Mircera

Time frame: Baseline up to 9 months

Number of Participants Who Received Concomitant Treatment (Known as Potentially Resistant Factors) for Renal Anemia

Time frame: Baseline up to 9 month